Cancer Risk

NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
NewLink Genetics Corporation voiced currently diagnosis of the initial studious in the national Phase 3 clinical hearing of the HyperAcute®-Pancreas cancer immunotherapy for patients who have successfully undergone pancreatic surgical resection.

Cancer Topics: Cancer, cancer immunotherapy, Clinical, HyperAcuteRPancreas, Immunotherapy, Initiates, NewLink, pancreas cancer, Pancreatic, Pancreatic Cancer, Phase, Pivotal, Resected, surgical resection, trial